U.S. markets closed
  • S&P 500

    4,429.10
    +26.44 (+0.60%)
     
  • Dow 30

    35,064.25
    +271.58 (+0.78%)
     
  • Nasdaq

    14,895.12
    +114.58 (+0.78%)
     
  • Russell 2000

    2,236.01
    +39.69 (+1.81%)
     
  • Crude Oil

    69.10
    +0.01 (+0.01%)
     
  • Gold

    1,806.50
    -2.40 (-0.13%)
     
  • Silver

    25.18
    -0.11 (-0.42%)
     
  • EUR/USD

    1.1839
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.2170
    +0.0330 (+2.79%)
     
  • GBP/USD

    1.3932
    +0.0047 (+0.34%)
     
  • USD/JPY

    109.7560
    +0.2880 (+0.26%)
     
  • BTC-USD

    40,952.36
    +1,026.04 (+2.57%)
     
  • CMC Crypto 200

    1,005.54
    +29.64 (+3.04%)
     
  • FTSE 100

    7,120.43
    -3.43 (-0.05%)
     
  • Nikkei 225

    27,728.12
    +144.04 (+0.52%)
     

What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Abiomed, Inc. (NASDAQ:ABMD) saw a decent share price growth in the teens level on the NASDAQGS over the last few months. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, what if the stock is still a bargain? Let’s examine Abiomed’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

View our latest analysis for Abiomed

What is Abiomed worth?

According to my price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 60.62x is currently trading slightly above its industry peers’ ratio of 57.25x, which means if you buy Abiomed today, you’d be paying a relatively sensible price for it. And if you believe that Abiomed should be trading at this level in the long run, then there should only be a fairly immaterial downside vs other industry peers. Is there another opportunity to buy low in the future? Since Abiomed’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

What does the future of Abiomed look like?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Abiomed's earnings growth are expected to be in the teens in the upcoming years, indicating a solid future ahead. This should lead to robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? ABMD’s optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at ABMD? Will you have enough confidence to invest in the company should the price drop below the industry PE ratio?

Are you a potential investor? If you’ve been keeping tabs on ABMD, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the optimistic forecast is encouraging for ABMD, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

It can be quite valuable to consider what analysts expect for Abiomed from their most recent forecasts. At Simply Wall St, we have the analysts estimates which you can view by clicking here.

If you are no longer interested in Abiomed, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.